- Home
- CMPS vs ERAS Comparison
CMPS vs ERAS Comparison
Compare CMPS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- ERAS
- Stock Information
- Founded
- CMPS 2020
- ERAS 2018
- Country
- CMPS United Kingdom
- ERAS United States
- Employees
- CMPS N/A
- ERAS N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CMPS Health Care
- ERAS Health Care
- Exchange
- CMPS Nasdaq
- ERAS Nasdaq
- Market Cap
- CMPS 422.4M
- ERAS 448.1M
- IPO Year
- CMPS 2020
- ERAS 2021
- Fundamental
- Price
- CMPS $4.21
- ERAS $1.41
- Analyst Decision
- CMPS Strong Buy
- ERAS Strong Buy
- Analyst Count
- CMPS 6
- ERAS 5
- Target Price
- CMPS $29.60
- ERAS $5.70
- AVG Volume (30 Days)
- CMPS 1.2M
- ERAS 1.3M
- Earning Date
- CMPS 02-27-2025
- ERAS 03-26-2025
- Dividend Yield
- CMPS N/A
- ERAS N/A
- EPS Growth
- CMPS N/A
- ERAS N/A
- EPS
- CMPS N/A
- ERAS N/A
- Revenue
- CMPS N/A
- ERAS N/A
- Revenue This Year
- CMPS N/A
- ERAS N/A
- Revenue Next Year
- CMPS N/A
- ERAS N/A
- P/E Ratio
- CMPS N/A
- ERAS N/A
- Revenue Growth
- CMPS N/A
- ERAS N/A
- 52 Week Low
- CMPS $3.17
- ERAS $1.41
- 52 Week High
- CMPS $12.75
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- CMPS 48.38
- ERAS 25.44
- Support Level
- CMPS $3.99
- ERAS $1.52
- Resistance Level
- CMPS $4.88
- ERAS $1.76
- Average True Range (ATR)
- CMPS 0.41
- ERAS 0.13
- MACD
- CMPS -0.01
- ERAS 0.00
- Stochastic Oscillator
- CMPS 26.89
- ERAS 0.00
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.